BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 22794353)

  • 1. Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight.
    Lolli G; Cozza G; Mazzorana M; Tibaldi E; Cesaro L; Donella-Deana A; Meggio F; Venerando A; Franchin C; Sarno S; Battistutta R; Pinna LA
    Biochemistry; 2012 Aug; 51(31):6097-107. PubMed ID: 22794353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules.
    Raaf J; Brunstein E; Issinger OG; Niefind K
    Chem Biol; 2008 Feb; 15(2):111-7. PubMed ID: 18291315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The catalytic subunit of human protein kinase CK2 structurally deviates from its maize homologue in complex with the nucleotide competitive inhibitor emodin.
    Raaf J; Klopffleisch K; Issinger OG; Niefind K
    J Mol Biol; 2008 Mar; 377(1):1-8. PubMed ID: 18242640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inclining the purine base binding plane in protein kinase CK2 by exchanging the flanking side-chains generates a preference for ATP as a cosubstrate.
    Yde CW; Ermakova I; Issinger OG; Niefind K
    J Mol Biol; 2005 Mar; 347(2):399-414. PubMed ID: 15740749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structure of the catalytic subunit of protein kinase CK2 from Zea mays at 2.1 A resolution.
    Niefind K; Guerra B; Pinna LA; Issinger OG; Schomburg D
    EMBO J; 1998 May; 17(9):2451-62. PubMed ID: 9564028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
    Sarno S; de Moliner E; Ruzzene M; Pagano MA; Battistutta R; Bain J; Fabbro D; Schoepfer J; Elliott M; Furet P; Meggio F; Zanotti G; Pinna LA
    Biochem J; 2003 Sep; 374(Pt 3):639-46. PubMed ID: 12816539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
    Battistutta R; Mazzorana M; Sarno S; Kazimierczuk Z; Zanotti G; Pinna LA
    Chem Biol; 2005 Nov; 12(11):1211-9. PubMed ID: 16298300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein kinase CK2 in health and disease: Structural bases of protein kinase CK2 inhibition.
    Battistutta R
    Cell Mol Life Sci; 2009 Jun; 66(11-12):1868-89. PubMed ID: 19387547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.
    Prudent R; Moucadel V; Laudet B; Barette C; Lafanechère L; Hasenknopf B; Li J; Bareyt S; Lacôte E; Thorimbert S; Malacria M; Gouzerh P; Cochet C
    Chem Biol; 2008 Jul; 15(7):683-92. PubMed ID: 18635005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ATP-binding site of protein kinase CK2 holds a positive electrostatic area and conserved water molecules.
    Battistutta R; Mazzorana M; Cendron L; Bortolato A; Sarno S; Kazimierczuk Z; Zanotti G; Moro S; Pinna LA
    Chembiochem; 2007 Oct; 8(15):1804-9. PubMed ID: 17768728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory influence of natural flavonoids on human protein kinase CK2 isoforms: effect of the regulatory subunit.
    Baier A; Nazaruk J; Galicka A; Szyszka R
    Mol Cell Biochem; 2018 Jul; 444(1-2):35-42. PubMed ID: 29188536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GTP plus water mimic ATP in the active site of protein kinase CK2.
    Niefind K; Pütter M; Guerra B; Issinger OG; Schomburg D
    Nat Struct Biol; 1999 Dec; 6(12):1100-3. PubMed ID: 10581548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid.
    Sekiguchi Y; Nakaniwa T; Kinoshita T; Nakanishi I; Kitaura K; Hirasawa A; Tsujimoto G; Tada T
    Bioorg Med Chem Lett; 2009 Jun; 19(11):2920-3. PubMed ID: 19414254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of 4,5,6,7-tetrahalogeno-1H-isoindole-1,3(2H)-diones as inhibitors of human protein kinase CK2.
    Golub AG; Yakovenko OY; Prykhod'ko AO; Lukashov SS; Bdzhola VG; Yarmoluk SM
    Biochim Biophys Acta; 2008 Jan; 1784(1):143-9. PubMed ID: 18021749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First inactive conformation of CK2 alpha, the catalytic subunit of protein kinase CK2.
    Raaf J; Issinger OG; Niefind K
    J Mol Biol; 2009 Mar; 386(5):1212-21. PubMed ID: 19361447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study.
    Meggio F; Pagano MA; Moro S; Zagotto G; Ruzzene M; Sarno S; Cozza G; Bain J; Elliott M; Deana AD; Brunati AM; Pinna LA
    Biochemistry; 2004 Oct; 43(40):12931-6. PubMed ID: 15461466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New protein kinase CK2 inhibitors: jumping out of the catalytic box.
    Prudent R; Cochet C
    Chem Biol; 2009 Feb; 16(2):112-20. PubMed ID: 19246001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors.
    Hundsdörfer C; Hemmerling HJ; Götz C; Totzke F; Bednarski P; Le Borgne M; Jose J
    Bioorg Med Chem; 2012 Apr; 20(7):2282-9. PubMed ID: 22377675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
    Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
    Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A structural insight into CK2 inhibition.
    Mazzorana M; Pinna LA; Battistutta R
    Mol Cell Biochem; 2008 Sep; 316(1-2):57-62. PubMed ID: 18626746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.